{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:12:00Z","timestamp":1783606320971,"version":"3.55.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203186"],"award-info":[{"award-number":["82203186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373428"],"award-info":[{"award-number":["82373428"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The \"Pioneer\" and \"Leading Goose\" R&D Program of Zhejiang","award":["2025C02073"],"award-info":[{"award-number":["2025C02073"]}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-NESTLE2022QN-0345"],"award-info":[{"award-number":["Y-NESTLE2022QN-0345"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2023ZD0501600"],"award-info":[{"award-number":["2023ZD0501600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Precis. Onc."],"DOI":"10.1038\/s41698-026-01387-0","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T18:06:44Z","timestamp":1775066804000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Neoadjuvant mFOLFOX6 plus camrelizumab and apatinib in colon cancer and biomarker research via spatiotemporal-omics profiling"],"prefix":"10.1038","volume":"10","author":[{"given":"Zhou","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liaoliao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanwen","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijia","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"1387_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1387_CR2","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109\u20133116 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR3","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343\u20132351 (2004).","journal-title":"N. Engl. J. Med."},{"key":"1387_CR4","doi-asserted-by":"crossref","unstructured":"Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 359, 1727\u20131733 (2002).","DOI":"10.1016\/S0140-6736(02)08651-8"},{"key":"1387_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham, D. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 355, 11\u201320 (2006).","journal-title":"N. Engl. J. Med."},{"key":"1387_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10585-018-9896-8","volume":"35","author":"M Alieva","year":"2018","unstructured":"Alieva, M., van Rheenen, J. & Broekman, M. L. D. Potential impact of invasive surgical procedures on primary tumor growth and metastasis. Clin. Exp. Metastasis 35, 319\u2013331 (2018).","journal-title":"Clin. Exp. Metastasis"},{"key":"1387_CR7","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1200\/JCO.24.00220","volume":"42","author":"C Peng","year":"2024","unstructured":"Peng, C. & Kircher, S. M. Neoadjuvant chemotherapy in colon cancer: more than just an optical illusion. J. Clin. Oncol. 42, 2949\u20132954 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR8","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/JCO.22.00046","volume":"41","author":"D Morton","year":"2023","unstructured":"Morton, D. et al. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J. Clin. Oncol. 41, 1541\u20131552 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR9","doi-asserted-by":"publisher","first-page":"LBA3503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3503","volume":"41","author":"LH Jensen","year":"2023","unstructured":"Jensen, L. H. et al. Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. J. Clin. Oncol. 41, LBA3503 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR10","unstructured":"Hu, H. et al. Neoadjuvant chemotherapy with oxaliplatin and fluoropyrimidine versus upfront surgery for locally advanced colon cancer: the randomized, Phase III OPTICAL Trial. J. Clin. Oncol. JCO2301889 (2024)."},{"key":"1387_CR11","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s00384-021-03945-3","volume":"36","author":"R Gosavi","year":"2021","unstructured":"Gosavi, R. et al. Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. Int J. Colorectal Dis. 36, 2063\u20132070 (2021).","journal-title":"Int J. Colorectal Dis."},{"key":"1387_CR12","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00384-023-04482-x","volume":"38","author":"MG Davey","year":"2023","unstructured":"Davey, M. G. et al. Evaluating the oncological safety of neoadjuvant chemotherapy in locally advanced colon carcinoma: a systematic review and meta-analysis of randomised clinical trials and propensity-matched studies. Int J. Colorectal Dis. 38, 193 (2023).","journal-title":"Int J. Colorectal Dis."},{"key":"1387_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1024345","volume":"12","author":"Z Liang","year":"2022","unstructured":"Liang, Z. et al. The role of neoadjuvant chemotherapy in patients with locally advanced colon cancer: A systematic review and meta-analysis. Front Oncol. 12, 1024345 (2022).","journal-title":"Front Oncol."},{"key":"1387_CR14","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1387_CR15","doi-asserted-by":"publisher","first-page":"S1389","DOI":"10.1016\/j.annonc.2022.08.016","volume":"33","author":"M Chalabi","year":"2022","unstructured":"Chalabi, M. et al. LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Ann. Oncol. 33, S1389 (2022).","journal-title":"Ann. Oncol."},{"key":"1387_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S2468-1253(21)00348-4","volume":"7","author":"H Hu","year":"2022","unstructured":"Hu, H. et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol. Hepatol. 7, 38\u201348 (2022).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"1387_CR17","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","volume":"27","author":"J Xu","year":"2021","unstructured":"Xu, J. et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, Phase II Trial. Clin. Cancer Res. 27, 1003\u20131011 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1387_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","volume":"24","author":"TK Choueiri","year":"2023","unstructured":"Choueiri, T. K. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 24, 228\u2013238 (2023).","journal-title":"Lancet Oncol."},{"key":"1387_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","volume":"181","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur. J. Cancer 181, 26\u201337 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1387_CR20","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka, S. et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603). J. Clin. Oncol. 38, 2053\u20132061 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR21","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1158\/1078-0432.CCR-18-2484","volume":"25","author":"J Xu","year":"2019","unstructured":"Xu, J. et al. Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study. Clin. Cancer Res. 25, 515\u2013523 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1387_CR22","unstructured":"Li, C. et al. Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05). J. Clin. Oncol. JCO2400795. (2024)."},{"key":"1387_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106858","volume":"88","author":"X Cai","year":"2020","unstructured":"Cai, X. et al. Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression. Int Immunopharmacol. 88, 106858 (2020).","journal-title":"Int Immunopharmacol."},{"key":"1387_CR24","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-018-0903-9","volume":"78","author":"LJ Scott","year":"2018","unstructured":"Scott, L. J. Apatinib: a review in advanced gastric cancer and other advanced cancers. Drugs 78, 747\u2013758 (2018).","journal-title":"Drugs"},{"key":"1387_CR25","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/1078-0432.CCR-19-2179","volume":"26","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 Blockade. Clin. Cancer Res 26, 1712\u20131724 (2020).","journal-title":"Clin. Cancer Res"},{"key":"1387_CR26","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1053\/j.gastro.2021.06.064","volume":"161","author":"M Bortolomeazzi","year":"2021","unstructured":"Bortolomeazzi, M. et al. Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts. Gastroenterology 161, 1179\u20131193 (2021).","journal-title":"Gastroenterology"},{"key":"1387_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2021.02.015","volume":"39","author":"K Bi","year":"2021","unstructured":"Bi, K. et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 39, 649\u201361.e5 (2021).","journal-title":"Cancer Cell"},{"key":"1387_CR28","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/j.ccell.2021.09.010","volume":"39","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. Cancer Cell 39, 1578\u20131593.e8 (2021).","journal-title":"Cancer Cell"},{"key":"1387_CR29","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","volume":"313","author":"J Galon","year":"2006","unstructured":"Galon, J. et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Sci. (N. Y., NY) 313, 1960\u20131964 (2006).","journal-title":"Sci. (N. Y., NY)"},{"key":"1387_CR30","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","volume":"23","author":"A Christofides","year":"2022","unstructured":"Christofides, A. et al. The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23, 1148\u20131156 (2022).","journal-title":"Nat. Immunol."},{"key":"1387_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","volume":"18","author":"A Sica","year":"2008","unstructured":"Sica, A. et al. Macrophage polarization in tumour progression. Semin Cancer Biol. 18, 349\u2013355 (2008).","journal-title":"Semin Cancer Biol."},{"key":"1387_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34824-2","volume":"13","author":"L Li","year":"2022","unstructured":"Li, L. et al. Spatially resolved proteomics via tissue expansion. Nat. Commun. 13, 7242 (2022).","journal-title":"Nat. Commun."},{"key":"1387_CR33","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med"},{"key":"1387_CR34","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.celrep.2016.10.009","volume":"17","author":"M Giannakis","year":"2016","unstructured":"Giannakis, M. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 17, 1206 (2016).","journal-title":"Cell Rep."},{"key":"1387_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1\u201310 (2013).","journal-title":"Immunity"},{"key":"1387_CR36","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865\u20131874 (2016).","journal-title":"Clin. Cancer Res."},{"key":"1387_CR37","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/imr.12650","volume":"283","author":"T Gebhardt","year":"2018","unstructured":"Gebhardt, T., Palendira, U., Tscharke, D. C. & Bedoui, S. Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance. Immunol. Rev. 283, 54\u201376 (2018).","journal-title":"Immunol. Rev."},{"key":"1387_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111381","volume":"127","author":"F Jiang","year":"2024","unstructured":"Jiang, F. et al. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy. Int. Immunopharmacol. 127, 111381 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"1387_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/imm.13710","volume":"171","author":"G Romagnoli","year":"2024","unstructured":"Romagnoli, G. et al. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis. Immunology 171, 198\u2013211 (2024).","journal-title":"Immunology"},{"key":"1387_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.cell.2020.06.001","volume":"182","author":"AM Luoma","year":"2020","unstructured":"Luoma, A. M. et al. Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. Cell 182, 655\u201371.e22 (2020).","journal-title":"Cell"},{"key":"1387_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","volume":"26","author":"M Chalabi","year":"2020","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566\u2013576 (2020).","journal-title":"Nat. Med."},{"key":"1387_CR42","doi-asserted-by":"publisher","first-page":"S449","DOI":"10.1016\/j.annonc.2020.08.602","volume":"31","author":"A Avallone","year":"2020","unstructured":"Avallone, A. et al. 491P Neoadjuvant nivolumab in early stage colorectal cancer. Ann. Oncol. 31, S449 (2020).","journal-title":"Ann. Oncol."},{"key":"1387_CR43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1200\/JCO.2025.43.4_suppl.207","volume":"43","author":"E Hissong","year":"2025","unstructured":"Hissong, E. et al. Neoadjuvant botensilimab (BOT) plus balstilimab (BAL) in resectable mismatch repair proficient (pMMR) and deficient (dMMR) colorectal cancer (CRC): NEST clinical trial update. J. Clin. Oncol. 43, 207 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR44","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1200\/JCO.2025.43.4_suppl.158","volume":"43","author":"M Ambrosini","year":"2025","unstructured":"Ambrosini, M. et al. Preoperative botensilimab (BOT) with or without balstilimab (BAL) for patients with resectable locally advanced pMMR or dMMR colon cancer: Results from the UNICORN trial by GONO. J. Clin. Oncol. 43, 158 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR45","doi-asserted-by":"publisher","first-page":"3252","DOI":"10.1038\/s41388-023-02835-y","volume":"42","author":"PM Kasi","year":"2023","unstructured":"Kasi, P. M. et al. Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer. Oncogene 42, 3252\u20133259 (2023).","journal-title":"Oncogene"},{"key":"1387_CR46","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/onc.2009.356","volume":"29","author":"A Tesniere","year":"2010","unstructured":"Tesniere, A. et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29, 482\u2013491 (2010).","journal-title":"Oncogene"},{"key":"1387_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.oraloncology.2019.06.016","volume":"95","author":"SJ Park","year":"2019","unstructured":"Park, S. J. et al. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer. Oral. Oncol. 95, 127\u2013135 (2019).","journal-title":"Oral. Oncol."},{"key":"1387_CR48","doi-asserted-by":"publisher","first-page":"586","DOI":"10.3389\/fonc.2020.00586","volume":"10","author":"Y Guan","year":"2020","unstructured":"Guan, Y. et al. FOLFOX Chemotherapy Ameliorates CD8 T Lymphocyte Exhaustion and Enhances Checkpoint Blockade Efficacy in Colorectal Cancer. Front Oncol. 10, 586 (2020).","journal-title":"Front Oncol."},{"key":"1387_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000496277","volume":"8","author":"M Kudo","year":"2019","unstructured":"Kudo, M. Combination cancer immunotherapy with molecular targeted agents\/anti-CTLA-4 antibody for hepatocellular carcinoma. Liver Cancer 8, 1\u201311 (2019).","journal-title":"Liver Cancer"},{"key":"1387_CR50","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41586-023-06002-x","volume":"618","author":"T Lazarov","year":"2023","unstructured":"Lazarov, T., Juarez-Carre\u00f1o, S., Cox, N. & Geissmann, F. Physiology and diseases of tissue-resident macrophages. Nature 618, 698\u2013707 (2023).","journal-title":"Nature"},{"key":"1387_CR51","doi-asserted-by":"crossref","unstructured":"Etzerodt, A. et al. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. J. Exp. Med. 217.(2020).","DOI":"10.1084\/jem.20191869"},{"key":"1387_CR52","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-021-03651-8","volume":"595","author":"M Casanova-Acebes","year":"2021","unstructured":"Casanova-Acebes, M. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595, 578\u2013584 (2021).","journal-title":"Nature"},{"key":"1387_CR53","doi-asserted-by":"publisher","first-page":"e50946","DOI":"10.1371\/journal.pone.0050946","volume":"7","author":"QW Zhang","year":"2012","unstructured":"Zhang, Q. W. et al. Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS ONE 7, e50946 (2012).","journal-title":"PLoS ONE"},{"key":"1387_CR54","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938\u2013945 (2015).","journal-title":"Nat. Med."},{"key":"1387_CR55","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369\u2013382 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"1387_CR56","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2022.02.021","volume":"185","author":"R Nalio Ramos","year":"2022","unstructured":"Nalio Ramos, R. et al. Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer. Cell 185, 1189\u2013207.e25 (2022).","journal-title":"Cell"},{"key":"1387_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add1967","volume":"9","author":"J Zhao","year":"2024","unstructured":"Zhao, J., Andreev, I. & Silva, H. M. Resident tissue macrophages: Key coordinators of tissue homeostasis beyond immunity. Sci. Immunol. 9, eadd1967 (2024).","journal-title":"Sci. Immunol."},{"key":"1387_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.100987","volume":"4","author":"X Bao","year":"2023","unstructured":"Bao, X. et al. An immunometabolism subtyping system identifies S100A9(+) macrophage as an immune therapeutic target in colorectal cancer based on multiomics analysis. Cell Rep. Med 4, 100987 (2023).","journal-title":"Cell Rep. Med"},{"key":"1387_CR59","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1593\/neo.121572","volume":"15","author":"A Boissonnas","year":"2013","unstructured":"Boissonnas, A. et al. CD8+ tumor-infiltrating T cells are trapped in the tumor-dendritic cell network. Neoplasia 15, 85\u201394 (2013).","journal-title":"Neoplasia"},{"key":"1387_CR60","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 638\u2013652 (2014).","journal-title":"Cancer Cell"},{"key":"1387_CR61","doi-asserted-by":"publisher","first-page":"E4041","DOI":"10.1073\/pnas.1720948115","volume":"115","author":"E Peranzoni","year":"2018","unstructured":"Peranzoni, E. et al. Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment. Proc. Natl. Acad. Sci. USA 115, E4041\u2013E4050 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1387_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101399","volume":"5","author":"X Bao","year":"2024","unstructured":"Bao, X. et al. A multiomics analysis-assisted deep learning model identifies a macrophage-oriented module as a potential therapeutic target in colorectal cancer. Cell Rep. Med. 5, 101399 (2024).","journal-title":"Cell Rep. Med."},{"key":"1387_CR63","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","volume":"40","author":"K Kersten","year":"2022","unstructured":"Kersten, K. et al. Spatiotemporal co-dependency between macrophages and exhausted CD8(+) T cells in cancer. Cancer Cell 40, 624\u201338.e9 (2022).","journal-title":"Cancer Cell"},{"key":"1387_CR64","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin, B. et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat. Immunol. 21, 442\u2013454 (2020).","journal-title":"Nat. Immunol."},{"key":"1387_CR65","doi-asserted-by":"crossref","unstructured":"Cotechini T., Atallah A., Grossman A. Tissue-Resident and Recruited Macrophages in Primary Tumor and Metastatic Microenvironments: Potential Targets in Cancer Therapy. Cells. 10.(2021).","DOI":"10.3390\/cells10040960"},{"key":"1387_CR66","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.2147\/CMAR.S206731","volume":"11","author":"C Wang","year":"2019","unstructured":"Wang, C. et al. MAPT promoter CpG island hypermethylation is associated with poor prognosis in patients with stage II colorectal cancer. Cancer Manag Res 11, 7337\u20137343 (2019).","journal-title":"Cancer Manag Res"},{"key":"1387_CR67","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.1200\/JCO.2008.21.6887","volume":"27","author":"L Pusztai","year":"2009","unstructured":"Pusztai, L. et al. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J. Clin. Oncol. 27, 4287\u20134292 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR68","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/sji.12329","volume":"82","author":"YM Mosaad","year":"2015","unstructured":"Mosaad, Y. M. Clinical Role of Human Leukocyte Antigen in Health and Disease. Scand. J. Immunol. 82, 283\u2013306 (2015).","journal-title":"Scand. J. Immunol."},{"key":"1387_CR69","doi-asserted-by":"crossref","unstructured":"Iafolla M. A. J. et al. Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis. JNCI Cancer Spectr. 5 (2021).","DOI":"10.1093\/jncics\/pkaa115"},{"key":"1387_CR70","doi-asserted-by":"crossref","unstructured":"Correale P. et al. Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1\/PD-L1 immune checkpoint blockade. J Immunother Cancer. 8.(2020).","DOI":"10.1136\/jitc-2020-000733"},{"key":"1387_CR71","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","volume":"16","author":"Y Yang","year":"2021","unstructured":"Yang, Y. et al. Updated Overall Survival Data and Predictive Biomarkers of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC in the Phase 3 ORIENT-11 Study. J. Thorac. Oncol. 16, 2109\u20132120 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"1387_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09840-6","volume":"22","author":"J Mei","year":"2022","unstructured":"Mei, J. et al. HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC. BMC Cancer 22, 738 (2022).","journal-title":"BMC Cancer"},{"key":"1387_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93807-3","volume":"11","author":"MF Senosain","year":"2021","unstructured":"Senosain, M. F. et al. HLA-DR cancer cells expression correlates with T cell infiltration and is enriched in lung adenocarcinoma with indolent behavior. Sci. Rep. 11, 14424 (2021).","journal-title":"Sci. Rep."},{"key":"1387_CR74","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1200\/JCO.21.02726","volume":"41","author":"C Gallois","year":"2023","unstructured":"Gallois, C. et al. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT\/IDEA Pooled Analysis of 11 Adjuvant Trials. J. Clin. Oncol. 41, 803\u2013815 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR75","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S1470-2045(22)00274-1","volume":"23","author":"C Antoniotti","year":"2022","unstructured":"Antoniotti, C. et al. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 23, 876\u2013887 (2022).","journal-title":"Lancet Oncol."},{"key":"1387_CR76","doi-asserted-by":"crossref","unstructured":"Lenz H. J. et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 12.(2024).","DOI":"10.1136\/jitc-2023-008409"},{"key":"1387_CR77","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1200\/JCO.2022.40.16_suppl.3500","volume":"40","author":"H Hu","year":"2022","unstructured":"Hu, H. et al. Perioperative chemotherapy with mFOLFOX6 or CAPOX for patients with locally advanced colon cancer (OPTICAL): A multicenter, randomized, phase 3 trial. J. Clin. Oncol. 40, 3500 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1387_CR78","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/S1470-2045(12)70348-0","volume":"13","author":"G Foxtrot Collaborative","year":"2012","unstructured":"Foxtrot Collaborative, G. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 13, 1152\u20131160 (2012).","journal-title":"Lancet Oncol."},{"key":"1387_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-529","volume":"10","author":"J Li","year":"2010","unstructured":"Li, J. et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 10, 529 (2010).","journal-title":"BMC Cancer"},{"key":"1387_CR80","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/j.1349-7006.2011.01939.x","volume":"102","author":"S Tian","year":"2011","unstructured":"Tian, S. et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102, 1374\u20131380 (2011).","journal-title":"Cancer Sci."},{"key":"1387_CR81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","volume":"12","author":"O Dworak","year":"1997","unstructured":"Dworak, O., Keilholz, L. & Hoffmann, A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J. Colorectal Dis. 12, 19\u201323 (1997).","journal-title":"Int J. Colorectal Dis."},{"key":"1387_CR82","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13046-023-02710-4","volume":"42","author":"L Liu","year":"2023","unstructured":"Liu, L. et al. Single-cell analysis reveals HBV-specific PD-1(+)CD8(+) TRM cells in tumor borders are associated with HBV-related hepatic damage and fibrosis in HCC patients. J. Exp. Clin. Cancer Res. 42, 152 (2023).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1387_CR83","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2021107739","volume":"41","author":"J Fan","year":"2022","unstructured":"Fan, J. et al. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes. EMBO J. 41, e107739 (2022).","journal-title":"EMBO J."},{"key":"1387_CR84","volume":"11","author":"X Sun","year":"2024","unstructured":"Sun, X. et al. A pathologically friendly strategy for determining the organ-specific spatial tumor microenvironment topology in lung adenocarcinoma through the integration of snRandom-seq and imaging mass cytometry. Adv. Sci. (Weinh.) 11, e2308892 (2024).","journal-title":"Adv. Sci. (Weinh.)"},{"key":"1387_CR85","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39173-2","volume":"14","author":"J Du","year":"2023","unstructured":"Du, J. et al. Selective oxidative protection leads to tissue topological changes orchestrated by macrophage during ulcerative colitis. Nat. Commun. 14, 3675 (2023).","journal-title":"Nat. Commun."},{"key":"1387_CR86","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1038\/s41596-023-00881-0","volume":"18","author":"J Windhager","year":"2023","unstructured":"Windhager, J. et al. An end-to-end workflow for multiplexed image processing and analysis. Nat. Protoc. 18, 3565\u20133613 (2023).","journal-title":"Nat. Protoc."},{"key":"1387_CR87","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41592-020-00998-0","volume":"17","author":"F Meier","year":"2020","unstructured":"Meier, F. et al. diaPASEF: parallel accumulation-serial fragmentation combined with data-independent acquisition. Nat. Methods 17, 1229\u20131236 (2020).","journal-title":"Nat. Methods"},{"key":"1387_CR88","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nmeth.4256","volume":"14","author":"AT Kong","year":"2017","unstructured":"Kong, A. T., Leprevost, F. V., Avtonomov, D. M., Mellacheruvu, D. & Nesvizhskii, A. I. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat. Methods 14, 513\u2013520 (2017).","journal-title":"Nat. Methods"},{"key":"1387_CR89","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1074\/mcp.TIR120.002048","volume":"19","author":"F Yu","year":"2020","unstructured":"Yu, F. et al. Fast quantitative analysis of timsTOF PASEF data with MSFragger and IonQuant. Mol. Cell Proteom. 19, 1575\u20131585 (2020).","journal-title":"Mol. Cell Proteom."},{"key":"1387_CR90","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"1387_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinforma. 14, 7 (2013).","journal-title":"BMC Bioinforma."},{"key":"1387_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"1387_CR93","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"1387_CR94","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell, S. et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ 389, e081123 (2025).","journal-title":"BMJ"}],"container-title":["npj Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01387-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01387-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01387-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:03:56Z","timestamp":1779840236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41698-026-01387-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1038\/s41698-026-01387-0","relation":{},"ISSN":["2397-768X"],"issn-type":[{"value":"2397-768X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}